New hope for controlling debilitating inflammation in rare immune disease
NCT ID NCT05104723
Summary
This early-stage study is testing whether the drug tofacitinib is safe and can help control severe inflammation in adults with chronic granulomatous disease (CGD). CGD is a rare immune disorder where people get frequent infections and often develop painful inflammation in their gut, skin, or lungs. Researchers will give 20 participants the drug as a pill for 3 months to see if it reduces their inflammation without causing serious side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC GRANULOMATOUS DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.